A Phase II Open-Label, Single Center Trial of Oral Decitabine-Cedazuridine (DEC-C) (Inqovi®) in Combination With Thioguanine (Tabloid®) in Patients With Relapsed or Refractory (R/R) Acute Myeloid Leukemia (AML)
Latest Information Update: 27 Mar 2025
At a glance
- Drugs Cedazuridine/decitabine (Primary) ; Tioguanine (Primary)
- Indications Acute myeloid leukaemia
- Focus Therapeutic Use
Most Recent Events
- 24 Mar 2025 Status changed from recruiting to withdrawn prior to enrolment.
- 11 Apr 2024 New trial record